Sign In
Buy EXAS
$104.91
+0 (+0%)
At Close: Jun 03, 2026
Does Exact Sciences (EXAS) Have the Potential to Rally 34.13% as Wall Street Analysts Expect?
10:55am, Thursday, 22'nd Aug 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 34.1% in Exact Sciences (EXAS). While the effectiveness of this highly sought-after metric is questionable, the
Exact Sciences (EXAS) Rides on Cologuard Sales, New Launches
10:25am, Thursday, 22'nd Aug 2024
Exact Sciences (EXAS) identifies more than 100 opportunities with payers and health systems to address the care gaps with Cologuard through screening programs.
Exact Sciences (EXAS) Enrolls First Patient in Pivotal MCED Study
09:46am, Thursday, 22'nd Aug 2024
Exact Sciences (EXAS) initiates the MCED Falcon Registry study, with Baylor Scott & White Health and Endeavor Health serving as the primary study sites.
Exact Sciences: Cost Optimization And Product Strength
06:51pm, Sunday, 18'th Aug 2024
Exact Sciences stock is down 35% since August 2021, now trading at around $58.75. The second quarter of 2024 (Q2) results beat expectations with revenue growth driven by the Cologuard screening segmen
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, shared new modeling data today describing the projected impact of the
Why You Should Add Exact Sciences (EXAS) to Your Portfolio
10:21am, Wednesday, 14'th Aug 2024
Exact Sciences' (EXAS) progress with strategic priority and strong solvency bode well.
Wall Street Analysts Predict a 45.04% Upside in Exact Sciences (EXAS): Here's What You Should Know
10:55am, Tuesday, 06'th Aug 2024
The consensus price target hints at a 45% upside potential for Exact Sciences (EXAS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings esti
Exact Sciences Analysts Slash Their Forecasts After Q2 Results
02:14pm, Thursday, 01'st Aug 2024
Exact Sciences Corporation EXAS reported better-than-expected second-quarter financial results on Wednesday.
Exact Sciences (EXAS) Q2 Loss Narrower Than Expected, Sales Beat
10:06am, Thursday, 01'st Aug 2024
Exact Sciences' (EXAS) second-quarter 2024 top-line results reflect robust revenues from the Screening and Precision Oncology segments.
Why Exact Sciences, Up 20%, Is 'Coiled To Snap Back' After Quarterly Beat
10:01am, Thursday, 01'st Aug 2024
Exact Sciences stock bounded higher Thursday after beating second-quarter expectations, signaling a return to growth for Cologuard.
Exact Sciences (EXAS) Reports Q2 Loss, Tops Revenue Estimates
08:31pm, Wednesday, 31'st Jul 2024
Exact Sciences (EXAS) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.45 per share a year ago.
Exact Sciences Corporation (EXAS) Q2 2024 Earnings Call Transcript
08:17pm, Wednesday, 31'st Jul 2024
Exact Sciences Corporation (NASDAQ:EXAS ) Q2 2024 Earnings Conference Call July 31, 2024 5:00 PM ET Company Participants Erik Holznecht - Manager, Investor Relations Kevin Conroy - Chairman and Chief
The Single Best Stock to Buy Under $50
12:11pm, Tuesday, 30'th Jul 2024
24/7 Wall Street Insights Early cancer detection is the first line of defense in preventing the disease's progression and reducing fatalities.
Exact Sciences (EXAS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
11:07am, Wednesday, 24'th Jul 2024
Exact Sciences (EXAS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Goldman Sachs Says Buy These 3 Stocks for Double-Digit Returns
09:32am, Monday, 22'nd Jul 2024
More than halfway through the year and the stock market is not done setting new all-time highs. With inflation ticking lower for the first time in four years possibly paving the way for interest rate
